New β-Lactam Antibiotics and Ceragenins – A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa

References

• Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016;20(1):136. doi:10.1186/s13054-016-1320-727329228
   PubMed Web of Science ®Google Scholar
• Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance. Genes Dis. 2019;6(2):109–119. doi:10.1016/j.gendis.2019.04.00131194018
   PubMed Web of Science ®Google Scholar
• Bucki R, Durnaś B, Wątek M, et al. Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics. Infect Drug Resist. 2018;11:77–86. doi:10.2147/IDR.S14533729391814
   PubMed Web of Science ®Google Scholar
• Juan C, Peña C, Oliver A. Host and pathogen biomarkers for severe pseudomonas aeruginosa infections. J Infect Dis. 2017;215(suppl_1):S44–S51. doi:10.1093/infdis/jiw29928375513
   PubMed Web of Science ®Google Scholar
• Gajdács M, Kárpáti K, Stájer A, et al. Insights on carbapenem-resistant Pseudomonas aeruginosa: phenotypic characterization of relevant isolates. Acta Biol Szegediensis. 2021;65:105–112. doi:10.14232/abs.2021.1.105-112
   Google Scholar
• Banzhaf M, Resendis-Antonio O, Zepeda-Mendoza ML. Uncovering the dynamic mechanisms of the pseudomonas aeruginosa quorum sensing and virulence networks using boolean modelling. IEEE Trans Nanobioscience. 2020;19(3):394–402. doi:10.1109/TNB.2020.297782032142451
   PubMed Web of Science ®Google Scholar
• Gajdács M, Baráth Z, Kárpáti K, et al. No correlation between biofilm formation, virulence factors, and antibiotic resistance in. Antibiotics. 2021;10(9). doi:10.3390/antibiotics10091134
   Web of Science ®Google Scholar
• Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4). doi:10.1128/CMR.00031-19
   PubMed Web of Science ®Google Scholar
• Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist. 2013;6:215–223. doi:10.2147/IDR.S3614024348053
   PubMedGoogle Scholar
• Giacobbe DR, Bassetti M, De Rosa FG, et al. Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018;16(4):307–320. doi:10.1080/14787210.2018.144738129493397
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-Avibactam: a Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Clin Ther. 2016;38(3):431–444. doi:10.1016/j.clinthera.2016.01.01826948862
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Rybak JM, Rybak MJ. The β-Lactams Strike Back: ceftazidime-Avibactam. Pharmacotherapy. 2015;35(8):755–770. doi:10.1002/phar.162226289307
   PubMed Web of Science ®Google Scholar
• Gentile I, Maraolo AE, Borgia G. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti Infect Ther. 2016;14(10):875–878. doi:10.1080/14787210.2016.123306027599088
   PubMed Web of Science ®Google Scholar
• Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant. Infect Drug Resist. 2018;11:1461–1472. doi:10.2147/IDR.S15044730254477
   PubMed Web of Science ®Google Scholar
• Surel UNK, Marzec M, Savege PB, Bucki R. Ceragenins-a new weapon to fight multidrug resistant bacterial infections. Med Studies. 2014;207–213. doi:10.5114/ms.2014.45428
   Google Scholar
• Hashemi M, Holden B, Durnas B, Bucki R, Savage P. Ceragenins as mimics of endogenous antimicrobial peptides. J Antimicrob Agents. 2017;3(1000141):2472–1212.1000141. doi:10.4172/2472-1212.1000141
   Google Scholar
• Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother. 2010;54(9):3708–3713. doi:10.1128/AAC.00380-1020585129
   PubMed Web of Science ®Google Scholar
• Hashemi MM, Holden BS, Savage PB. Ceragenins as non-peptide mimics of endogenous antimicrobial peptides. Fighting Antimicrobial Resist. 2018;1:139–169.
   Google Scholar
• Leszczynska K, Namiot D, Byfield FJ, et al. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. J Antimicrob Chemother. 2013;68(3):610–618. doi:10.1093/jac/dks43423134677
   PubMed Web of Science ®Google Scholar
• Durnaś B, Wnorowska U, Pogoda K, et al. Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites. PLoS One. 2016;11(6):e0157242. doi:10.1371/journal.pone.015724227315208
   PubMed Web of Science ®Google Scholar
• Lara D, Feng Y, Bader J, Savage PB, Maldonado RA. Anti-trypanosomatid activity of ceragenins. J Parasitol. 2010;96(3):638–642. doi:10.1645/GE-2329.119958044
   PubMed Web of Science ®Google Scholar
• Howell MD, Streib JE, Kim BE, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol. 2009;129(11):2668–2675. doi:10.1038/jid.2009.12019516269
   PubMed Web of Science ®Google Scholar
• Chmielewska SJ, Skłodowski K, Piktel E, et al. NDM-1 Carbapenemase-Producing Enterobacteriaceae are Highly Susceptible to Ceragenins CSA-13, CSA-44, and CSA-131. Infect Drug Resist. 2020;13:3277–3294. doi:10.2147/IDR.S26157933061475
   PubMed Web of Science ®Google Scholar
• Hashemi MM, Holden BS, Taylor MF, et al. Antibacterial and Antifungal Activities of Poloxamer Micelles Containing Ceragenin CSA-131 on Ciliated Tissues. Molecules. 2018;23(3):596. doi:10.3390/molecules23030596
   Web of Science ®Google Scholar
• Ozbek-Celik B, Damar-Celik D, Mataraci-Kara E, Bozkurt-Guzel C, Savage PB. Comparative in vitro activities of first and second-generation ceragenins alone and in combination with antibiotics against multidrug-resistant. Antibiotics. 2019;8(3). doi:10.3390/antibiotics8030130
   Web of Science ®Google Scholar
• EUCAST. Antimicrobial susceptibility testing (AST) of bacteria. Disk diffusion methodology. Detailed description of the EUCAST disk diffusion test. Version 9.0, 2021, https://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/
   Google Scholar
• Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2003;41(10):4623–4629. doi:10.1128/jcm.41.10.4623-4629.200314532193
   PubMed Web of Science ®Google Scholar
• Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J Clin Microbiol. 2008;46(12):4083–4086. doi:10.1128/JCM.01408-0818923005
   PubMed Web of Science ®Google Scholar
• EUCAST. Antimicrobial susceptibility testing (AST) of bacteria. MIC determination of non-fastidious and fastidious organisms. Version 3.0, 2021 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/MIC_testing/Reading_guide_BMD_v_3.0_2021.pdf
   Google Scholar
• Ding B, Guan Q, Walsh JP, et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem. 2002;45(3):663–669. doi:10.1021/jm010507011806717
   PubMed Web of Science ®Google Scholar
• Hashemi MM, Rovig J, Weber S, Hilton B, Forouzan MM, Savage PB. Susceptibility of colistin-resistant, gram-negative bacteria to antimicrobial peptides and ceragenins. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.00292-17
   Web of Science ®Google Scholar
• Pollard JE, Snarr J, Chaudhary V, et al. In vitro evaluation of the potential for resistance development to ceragenin CSA-13. J Antimicrob Chemother. 2012;67(11):2665–2672. doi:10.1093/jac/dks27622899801
   PubMed Web of Science ®Google Scholar
• Leszczyńska K, Namiot A, Cruz K, et al. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections. J Appl Microbiol. 2011;110(1):229–238. doi:10.1111/j.1365-2672.2010.04874.x20961363
   PubMed Web of Science ®Google Scholar
• Olekson MA, You T, Savage PB, Leung KP. Antimicrobial ceragenins inhibit biofilms and affect mammalian cell viability and migration. FEBS Open Bio. 2017;7(7):953–967. doi:10.1002/2211-5463.12235
   PubMed Web of Science ®Google Scholar
• Piktel E, Markiewicz KH, Wilczewska AZ, et al. Quantification of Synergistic Effects of Ceragenin CSA-131 combined with iron oxide magnetic nanoparticles against cancer cells. Int J Nanomedicine. 2020;15:4573–4589. doi:10.2147/IJN.S25517032606693
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. 2021 https://www.eucast.org/eucast_news/news_singleview/?tx_ttnews%5Btt_news%5D=406&cHash=9a92d976312c67c9b935f1f75bb5b71a
   Google Scholar
• Mouton JW, Muller AE, Canton R, Giske C, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables-authors’ response. J Antimicrob Chemother. 2018;73(9):2585–2586. doi:10.1093/jac/dky19530137389
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Rabine S, Hackel M, et al. Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(2):1067–1078. doi:10.1128/AAC.02379-1526643349
   PubMed Web of Science ®Google Scholar
• Dalmolin TV, de Lima-morales D, Barth AL. Plasmid-mediated colistin resistance: what do we know? J Infect. 2018;1(2). doi:10.29245/2689-9981/2018/2.1109
   Google Scholar
• Almutairy R, Aljrarri W, Noor A, et al. Impact of Colistin Dosing on the Incidence of Nephrotoxicity in a Tertiary Care Hospital in Saudi Arabia. Antibiotics. 2020;9(8). doi:10.3390/antibiotics9080485
   Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: for Whom, When, and How. Front Public Health. 2019;7:151. doi:10.3389/fpubh.2019.0015131245348
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527. doi:10.7573/dic.21252729872449
   PubMedGoogle Scholar
• Carvalhaes CG, Shortridge D, Sader HS, Castanheira M. Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. Antimicrob Agents Chemother. 2020;64(3). doi:10.1128/AAC.02177-19
   Web of Science ®Google Scholar
• Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9). doi:10.1128/AAC.00567-17
   Web of Science ®Google Scholar
• Buehrle DJ, Shields RK, Chen L, et al. Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016;60(5):3227–3231. doi:10.1128/AAC.02969-1526976862
   PubMed Web of Science ®Google Scholar
• Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis. 2017;62:39–43. doi:10.1016/j.ijid.2017.06.00728610832
   PubMed Web of Science ®Google Scholar
• Grupper M, Sutherland C, Nicolau DP. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. Antimicrob Agents Chemother. 2017;61(10). doi:10.1128/AAC.00875-17
   Web of Science ®Google Scholar
• Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2017;61(12). doi:10.1128/AAC.01858-17
   Web of Science ®Google Scholar
• Mirza HC, Hortaç E, Koçak AA, et al. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: a two-centre study. J Glob Antimicrob Resist. 2020;20:334–338. doi:10.1016/j.jgar.2019.09.01631568882
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Brigman HV, Zucchi PC, et al. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. J Glob Antimicrob Resist. 2020;22:689–694. doi:10.1016/j.jgar.2020.04.01732353524
   PubMed Web of Science ®Google Scholar
• Sid Ahmed MA, Khan FA, Sultan AA, et al. β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar. Antimicrob Resist Infect Control. 2020;9(1):170. doi:10.1186/s13756-020-00838-y33131487
   PubMed Web of Science ®Google Scholar
• Evans SR, Tran TTT, Hujer AM, et al. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis. 2019;68(11):1823–1830. doi:10.1093/cid/ciy80130239599
   PubMed Web of Science ®Google Scholar
• Montravers P, Bassetti M. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018;31(6):587–593. doi:10.1097/QCO.000000000000049030299359
   PubMed Web of Science ®Google Scholar
• Giani T, Arena F, Pollini S, et al. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2018;73(3):664–671. doi:10.1093/jac/dkx45329216350
   PubMed Web of Science ®Google Scholar
• Patel TS, Pogue JM, Mills JP, Kaye KS. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Future Microbiol. 2018;13:971–983. doi:10.2217/fmb-2018-005429692218
   PubMed Web of Science ®Google Scholar
• Amorese V, Donadu M, Usai D, et al. In vitro activity of essential oils against Pseudomonas aeruginosa isolated from infected hip implants. J Infect Dev Ctries. 2018;12(11):996–1001. doi:10.3855/jidc.1098832012130
   PubMed Web of Science ®Google Scholar
• Donadu M, Usai D, Pinna A, et al. In vitro activity of hybrid lavender essential oils against multidrug resistant strains of Pseudomonas aeruginosa. J Infect Dev Ctries. 2018;12(1):9–14. doi:10.3855/jidc.992031628828
   PubMed Web of Science ®Google Scholar
• Chaves-López C, Usai D, Donadu MG, et al. Potential of Borojoa patinoi Cuatrecasas water extract to inhibit nosocomial antibiotic resistant bacteria and cancer cell proliferation in vitro. Food Funct. 2018;9(5):2725–2734. doi:10.1039/c7fo01542a29658045
   PubMed Web of Science ®Google Scholar
• Bozkurt Guzel C, Oyardi O, Savage P. Comparative in vitro antimicrobial activities of CSA-142 and CSA-192, second-generation ceragenins, with CSA-13 against various microorganisms. J Chemother. 2018;30(6–8):332–337. doi:10.1080/1120009X.2018.153456730663553
   PubMed Web of Science ®Google Scholar
• Vila-Farrés X, Callarisa AE, Gu X, Savage PB, Giralt E, Vila J. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents. 2015;46(5):568–571. doi:10.1016/j.ijantimicag.2015.08.00326395218
   PubMed Web of Science ®Google Scholar
• Bozkurt Güzel C, Avci NM, Savage P. Activities of the Cationic Steroid Antibiotics CSA-13, CSA-131, CSA-138, CSA-142, and CSA-192 Against Carbapenem-resistant. Turk J Pharm Sci. 2020;17(1):63–67. doi:10.4274/tjps.galenos.2018.2656632454762
   PubMed Web of Science ®Google Scholar
• Wnorowska U, Piktel E, Durnaś B, Fiedoruk K, Savage PB, Bucki R. Use of ceragenins as a potential treatment for urinary tract infections. BMC Infect Dis. 2019;19(1):369. doi:10.1186/s12879-019-3994-331046689
   PubMed Web of Science ®Google Scholar
• Durnaś B, Piktel E, Wątek M, et al. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo. BMC Microbiol. 2017;17(1):167. doi:10.1186/s12866-017-1075-628747178
   PubMed Web of Science ®Google Scholar
• Wnorowska U, Niemirowicz K, Myint M, et al. Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58. Antimicrob Agents Chemother. 2015;59(7):3808–3815. doi:10.1128/AAC.00421-1525870055
   PubMed Web of Science ®Google Scholar
• Nagant C, Pitts B, Stewart PS, Feng Y, Savage PB, Dehaye JP. Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa. Microbiologyopen. 2013;2(2):318–325. doi:10.1002/mbo3.7723436807
   PubMed Web of Science ®Google Scholar
• Latorre MC, Pérez-Granda MJ, Savage PB, et al. Endotracheal tubes coated with a broad-spectrum antibacterial ceragenin reduce bacterial biofilm in an in vitro bench top model. J Antimicrob Chemother. 2021;76(5):1168–1173. doi:10.1093/jac/dkab01933544817
   PubMed Web of Science ®Google Scholar
• Gu X, Jennings JD, Snarr J, Chaudhary V, Pollard JE, Savage PB. Optimization of ceragenins for prevention of bacterial colonization of hydrogel contact lenses. Invest Ophthalmol Vis Sci. 2013;54(9):6217–6223. doi:10.1167/iovs.13-1266423970466
   PubMed Web of Science ®Google Scholar
• Sinclair KD, Pham TX, Williams DL, Farnsworth RW, Loc-Carrillo CM, Bloebaum RD. Model development for determining the efficacy of a combination coating for the prevention of perioperative device related infections: a pilot study. J Biomed Mater Res B Appl Biomater. 2013;101(7):1143–1153. doi:10.1002/jbm.b.3292423564717
   PubMed Web of Science ®Google Scholar
• Williams DL, Haymond BS, Beck JP, et al. In vivo efficacy of a silicone‒cationic steroid antimicrobial coating to prevent implant-related infection. Biomaterials. 2012;33(33):8641–8656. doi:10.1016/j.biomaterials.2012.08.00322940221
   PubMed Web of Science ®Google Scholar
• Schindeler A, Yu NY, Cheng TL, et al. Local delivery of the cationic steroid antibiotic CSA-90 enables osseous union in a rat open fracture model of Staphylococcus aureus infection. J Bone Joint Surg Am. 2015;97(4):302–309. doi:10.2106/JBJS.N.0084025695982
   PubMed Web of Science ®Google Scholar
• Hashemi MM, Rovig J, Bateman J, et al. Preclinical testing of a broad-spectrum antimicrobial endotracheal tube coated with an innate immune synthetic mimic. J Antimicrob Chemother. 2018;73(1):143–150. doi:10.1093/jac/dkx34729029265
   PubMed Web of Science ®Google Scholar